AZB & Partners and White & Case LLP have guided Sun Pharmaceutical Holdings USA, Inc., a U.S. subsidiary of Sun Pharmaceutical Industries, on its acquisition of Organon, a global healthcare company. Cyril Amarchand Mangaldas and Sullivan & Cromwell LLP advised Organon on this transaction.
Sun Pharma and Organon have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for USD 14.00 per share in an all‑cash transaction with an enterprise valuation of USD 11.75 billion.
“The transaction has been approved by the Boards of Directors of both Sun Pharma and Organon and is subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders,” Sun Pharma noted in an exchange filing.
The proposed acquisition of Organon is aligned with Sun Pharma’s strategy of growing its Innovative Medicines business. The deal also enables Sun Pharma’s entry into biosimilars as a Top-10 global player.
CAM’s transaction team was led by partners Ruetveij Pandya and Saloni Shroff with assistance from principal associate Abhilasha Malpani and associates Sajith Anjickal, Chelsea Sawlani, Neelanshi Gupta, Simran Srivastava, and Shravan Subramanian.
Partner (Co-Head – Private Client and Head – International Business Development) Rishabh Shroff, provided strategic inputs and guidance. Partner Meeta Kurpad with support from associates Manasvin Andra advised on financing aspects of the transaction.
